MedImpact Holdings Inc. is planning to release a Stelara (ustekinumab) biosimilar, according to a recent news release .

The unbranded ustekinumab-aekn biosimilar will be available for purchase from Birdi, Inc. by any licensed specialty pharmacy at a rate of 95% less than Stelara, the news release says.

Anda, a Teva Pharmaceuticals USA affiliate, will distribute it. It is expected to be available January 1, 2026.

This announcement is part of MedImpact’s broader plan to enhance price transparency and reduce the industry’s reliance on rebates, the news release says. Private-label versions sold by other PBMs are available exclusively through the pharmacies that they own.

“MedImpact’s specialty strategy is deeply rooted in the principle that pharmacies, members, and payers should not have

See Full Page